Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 11,338 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 228
States / cities: Birmingham, Alabama • Columbiana, Alabama • Gulf Shores, Alabama + 225 more

Conditions: HIV, Chronic Disease
Interventions: Patient Navigation; Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension, Hypotension, Edema, Congestive Heart Failure
Interventions: furosemide, placebo; Drug
Lead sponsor: University of Calgary; Other
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Catheters, Indwelling
Interventions: Alfimeprase; Drug
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
Interventions: ActiveCare CECT device, Enoxaparin; Device · Drug
Lead sponsor: Medical Compression Systems; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 9
States / cities: La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab; Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 889
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 593 more

Conditions: Endometrial Cancer, Weight Changes
Interventions: behavioral dietary intervention, counseling intervention, educational intervention, preventative dietary intervention, quality-of-life assessment; Behavioral · Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Vaccines, Pneumococcal
Interventions: 13 valent pneumococcal conjugate vaccine, 7vPnc pneumococcal conjugate vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 98 Days
Enrollment: 666 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 37
States / cities: Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 31 more

Conditions: Cardiovascular Risk, Chronic Kidney Disease, Inflammation
Interventions: Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 6,385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 181
States / cities: Birmingham, Alabama • Montgomery, Alabama • Glendale, Arizona + 140 more

Conditions: Heart Diseases, Hypertension, Pulmonary
Interventions: tezosentan, placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Stanford, California • New York, New York • Durham, North Carolina + 5 more

Conditions: Mitral Valve Insufficiency, Coronary Artery Disease
Interventions: Mitral Valve Repair with Annuloplasty, Mitral Valve Replacement; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 18
States / cities: Los Angeles, California • Atlanta, Georgia • Marietta, Georgia + 15 more

Conditions: Brain Tumor
Interventions: Magnetic Resonance Fingerprinting; Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Relapsed Sarcomas
Interventions: Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil); Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Lymphoblastic Leukemia (ALL)
Interventions: Vincristine Sulfate Liposomes Injection (VSLI), Vincristine Sulfate Injection (VSI); Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 60 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • Atlanta, Georgia + 11 more

Conditions: Kidney Stone, Kidney Calculi, Ureteral Calculi, Ureterolithiasis, Urolithiasis
Interventions: Lithotripter; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hepatitis
Interventions: Larsucosterol, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 98
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more

Conditions: Primary Brain Tumor
Interventions: NeuroBlate® System Therapy; Procedure
Lead sponsor: Monteris Medical; Industry
Eligibility: Not listed
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: New Haven, Connecticut • Kansas City, Kansas • Kansas City, Missouri + 5 more

Conditions: Degenerative Disc Disease
Interventions: Rexlemestrocel-L, Rexlemestrocel-L + HA Mixture, Placebo; Drug
Lead sponsor: Mesoblast, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 47
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 42 more

Conditions: Prostate Cancer
Interventions: Reiki, Pretend Reiki, Rest / Guided Imagery; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Male only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Endometrial Cancer
Interventions: conjugated estrogens; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 2,108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 149
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 99 more

Conditions: Multiple Sclerosis
Interventions: Placebo, 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP); Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more

Conditions: Asymptomatic
Interventions: Contrast-enhanced Magnetic Resonance Imaging, Digital Tomosynthesis Mammography, Quality-of-Life Assessment, Questionnaire Administration; Diagnostic Test · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 1,516 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 67
States / cities: Gilbert, Arizona • Pasadena, California • Denver, Colorado + 54 more

Conditions: Soft Tissue Sarcoma
Interventions: Palifosfamide-Tris, doxorubicin, Placebo; Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more

Conditions: Renal Cell Carcinoma, Mantle-Cell Lymphoma, Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3
Interventions: SGN-CD70A; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 17
States / cities: Birmingham, Alabama • Duarte, California • Maywood, Illinois + 14 more

Search by objective public record fields.

Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension

Randomized Trial of an HIV Navigation Program for Early Palliative Care

Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure

Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Lifestyle Change and Quality of Life in Obese Patients With Stage I/II Endometrial Cancer in Remission

Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation

Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL

Comparison of Lithotripsy Urolithiasis Machines

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry

Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain

Reiki/Energy Healing in Prostate Cancer

Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

Safety Study of SGN-CD70A in Cancer Patients